Most Recent Articles by Stan Grossman
A survey showed 67.3% of patient advocacy organizations received industry funding, while 11.9% received more than half of their funding from industry.
Katherine A. Roberts, MD, FACE, ECNU, discusses her choice to opt out of Medicare and offers advice to physicians considering doing the same.
Intrathecal dosing of neural progenitors appears to be safe and well tolerated in patients with progressive multiple sclerosis.
Investigational agent has the potential to repair damaged myelin sheath and restore function in patients with secondary-progressive multiple sclerosis.
Patients with MS were likely to experience relapses for the first time or relapse continuation between the ages of 27 and 47 years.
More Articles by Stan Grossman
Neurology Advisor Articles
- Increased Mortality in Parkinson's Disease Linked to Low Antidepressant Adherence
- Age, Gender, and Cognition Predict Weight Loss in Parkinson's Disease
- MRI in Parkinson's Disease: Expanding Usability for Better Diagnostics
- Parkinson's: Sleep Disturbances Affect Clinical Motor Subtypes, Disability
- The Handoff: Your Week in Neurology News - 9/21/17
- Exenatide Presents Exciting Therapeutic Possibilities for Parkinson's Disease
- Cognitive Decline Related to Site Specific Mid-Life Adiposity
- Parkinson's, REM Sleep Disorder Combination Linked to Cognitive Decline
- Higher Doses of Pregabalin for Neuropathic Pain: Is it Safe?
- Buccal, Nasal Midazolam Most Cost-Effective for Pediatric Status Epilepticus
- Zika Virus Associated With High Risk for Neurologic Complications in Adults
- Evolocumab Has No Effect on Cognition in Patients Attaining Very Low Levels of LDL Cholesterol
- Acute Oxygen Therapy for Cluster Headahce Not Prohibitively Expensive
- β-2 Adrenergic Agonists Linked to α-synuclein Transcription and Risk of PD
- Little Evidence to Support Doctor, Patient Electronic Communication Guidelines